Clavulanic acid
Augmentin, Timentin (clavulanic acid) is a small molecule pharmaceutical. Clavulanic acid was first approved as Augmentin '250' on 1984-08-06. It is used to treat haemophilus infections, otitis media, and staphylococcal infections in the USA.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
Combinations
Augmentin (generic drugs available since 2002-03-14, discontinued: Timentin)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Amoxicillin
+
Clavulanate potassium
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| AUGMENTIN '125' | USAntibiotics | N-050575 RX | 1984-08-06 | 1 products, RLD |
| AUGMENTIN '250' | USAntibiotics | N-050575 RX | 1984-08-06 | 1 products, RLD, RS |
| AUGMENTIN '875' | USAntibiotics | N-050720 RX | 1996-02-13 | 1 products, RLD |
| AUGMENTIN ES-600 | USAntibiotics | N-050755 RX | 2001-06-22 | 1 products, RLD |
Show 9 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| augmentin | New Drug Application | 2023-03-21 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| haemophilus infections | EFO_1001127 | D006192 | — |
| otitis media | EFO_0004992 | D010033 | H66.9 |
| staphylococcal infections | — | D013203 | A49.01 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
514 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Major depressive disorder | D003865 | EFO_0003761 | F22 | 11 | 24 | 30 | 51 | 20 | 129 |
| Depression | D003863 | F33.9 | 5 | 16 | 19 | 50 | 35 | 117 | |
| Healthy volunteers/patients | — | 24 | — | — | 4 | 4 | 32 | ||
| Anxiety disorders | D001008 | EFO_0006788 | F41.1 | 3 | 2 | 6 | 8 | 4 | 22 |
| Depressive disorder | D003866 | EFO_1002014 | F32.A | 4 | 1 | 6 | 2 | 3 | 15 |
| Anxiety | D001007 | EFO_0005230 | F41.1 | — | 1 | 3 | 5 | 6 | 14 |
| Schizophrenia | D012559 | EFO_0000692 | F20 | — | — | 2 | 8 | 1 | 11 |
| Alzheimer disease | D000544 | EFO_0000249 | F03 | 1 | 1 | 3 | 4 | 2 | 10 |
| Bipolar disorder | D001714 | EFO_0000289 | F30.9 | 1 | 2 | 3 | 2 | 2 | 9 |
| Obsessive-compulsive disorder | D009771 | EFO_0004242 | F42 | — | — | 1 | 6 | 1 | 8 |
Show 47 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Treatment-resistant depressive disorder | D061218 | 1 | — | 7 | — | 1 | 9 | ||
| Neoplasms | D009369 | C80 | 1 | 1 | 4 | — | 1 | 7 | |
| Cocaine-related disorders | D019970 | F14 | 1 | 5 | 1 | — | — | 6 | |
| Mood disorders | D019964 | EFO_0004247 | F30-F39 | — | 1 | 1 | — | 2 | 4 |
| Parkinson disease | D010300 | EFO_0002508 | G20 | — | 2 | 2 | — | 1 | 4 |
| Hot flashes | D019584 | — | — | 1 | — | 3 | 4 | ||
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 1 | 1 | — | 1 | 3 |
| Opioid-related disorders | D009293 | EFO_0005611 | F11 | — | 1 | 1 | — | — | 2 |
| Hiv infections | D015658 | EFO_0000764 | B20 | — | — | 2 | — | — | 2 |
| Fibromyalgia | D005356 | EFO_0005687 | M79.1 | — | 1 | 1 | — | 1 | 2 |
Show 24 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Menopause | D008593 | EFO_0003922 | N95 | — | 1 | — | — | 1 | 2 |
| Ischemic stroke | D000083242 | 1 | 2 | — | — | — | 2 | ||
| Male infertility | D007248 | EFO_0004248 | N46 | — | 1 | — | — | — | 1 |
| Chronic hepatitis c | D019698 | EFO_0004220 | B18.2 | — | 1 | — | — | — | 1 |
| Aphasia | D001037 | HP_0002381 | R47.01 | — | 1 | — | — | — | 1 |
| Glioma | D005910 | EFO_0000520 | — | 1 | — | — | — | 1 | |
| Chronic kidney failure | D007676 | EFO_0003884 | N18.6 | — | 1 | — | — | — | 1 |
| Bereavement | D001601 | — | 1 | — | — | — | 1 | ||
| Attention deficit disorder with hyperactivity | D001289 | EFO_0003888 | F90 | — | 1 | — | — | — | 1 |
| Neurodevelopmental disorders | D065886 | F89 | — | 1 | — | — | — | 1 |
Show 6 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Spinal cord injuries | D013119 | EFO_1001919 | 2 | — | — | — | 1 | 3 | |
| Substance-related disorders | D019966 | EFO_0003890 | F13 | 1 | — | — | — | 1 | 2 |
| Autism spectrum disorder | D000067877 | F84.0 | 1 | — | — | — | 1 | 2 | |
| Stress urinary incontinence | D014550 | HP_0010992 | 1 | — | — | — | — | 1 | |
| Fecal incontinence | D005242 | R15 | 1 | — | — | — | — | 1 | |
| Hepacivirus | D016174 | 1 | — | — | — | — | 1 | ||
| Premature ejaculation | D061686 | HP_0012876 | F52.4 | 1 | — | — | — | — | 1 |
| Respiratory insufficiency | D012131 | HP_0002093 | J96.9 | 1 | — | — | — | — | 1 |
| Hypercapnia | D006935 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | — | — | — | 4 | 4 |
| Pharmacokinetics | D010599 | — | — | — | — | 2 | 2 | ||
| Cognition | D003071 | EFO_0003925 | — | — | — | — | 2 | 2 | |
| Perimenopause | D047648 | — | — | — | — | 1 | 1 | ||
| Pregnancy | D011247 | EFO_0002950 | Z33.1 | — | — | — | — | 1 | 1 |
| Wounds and injuries | D014947 | T14.8 | — | — | — | — | 1 | 1 | |
| Chronic disease | D002908 | — | — | — | — | 1 | 1 | ||
| Brain injuries | D001930 | S06.9 | — | — | — | — | 1 | 1 | |
| Alcohol-related disorders | D019973 | F10 | — | — | — | — | 1 | 1 | |
| Suicidal ideation | D059020 | EFO_0004320 | R45.851 | — | — | — | — | 1 | 1 |
Show 19 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | CLAVULANIC ACID |
| INN | clavulanic acid |
| Description | Clavulanic acid is antibiotic isolated from Streptomyces clavuligerus. It acts as a suicide inhibitor of bacterial beta-lactamase enzymes. It has a role as an antibacterial drug, a bacterial metabolite, an anxiolytic drug and an EC 3.5.2.6 (beta-lactamase) inhibitor. It is a conjugate acid of a clavulanate. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | O=C(O)[C@H]1/C(=C/CO)O[C@@H]2CC(=O)N21 |
Identifiers
| PDB | — |
| CAS-ID | 58001-44-8 |
| RxCUI | 21216 |
| ChEMBL ID | CHEMBL777 |
| ChEBI ID | 48947 |
| PubChem CID | 5280980 |
| DrugBank | DB00766 |
| UNII ID | 23521W1S24 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 26,393 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
67,928 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more